September 19, 2014 8:34 PM ET

Biotechnology

Company Overview of Altus Pharmaceuticals Inc.

Company Overview

On January 22, 2013, Altus Pharmaceuticals Inc went out of business as per its Chapter 7 liquidation filing under bankruptcy. Altus Pharmaceuticals Inc., together with its subsidiaries, focuses on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. Its lead product candidates include ALTU-238, completed Phase II clinical trial in adults, is a crystallized formulation of human growth hormone for the treatment of hormone deficiency and related disorders; and ALTU-237, completed Phase I clinical trial, which is used for the treatment of hyperoxalurias and kidney stones. The company’s preclinical research a...

610 Lincoln Street

Waltham, MA 02451

United States

Founded in 1992

33 Employees

Phone:

781-373-6000

Fax:

781-373-6001

Key Executives for Altus Pharmaceuticals Inc.

Altus Pharmaceuticals Inc. does not have any Key Executives recorded.

Altus Pharmaceuticals Inc. Key Developments

SEC Revokes Registration Of Securities Of Altus Pharmaceuticals

An Administrative Law Judge issued an Order Making Findings and Revoking Registrations as to Altus Pharmaceuticals, Inc. by Default (Default Order). The Default Order found that the company has securities registered with the Securities and Exchange Commission (SEC) pursuant to Section 12(g) of the Securities Exchange Act of 1934, failed to file required periodic reports, and that the evidence supported revocation of its registered securities as necessary or appropriate for the protection of investors.

SEC Orders Hearings On Registration Suspension Or Revocation Against Altus Pharmaceuticals, Inc. For Failure To Make Required Periodic Filings

In conjunction with trading suspension, Securities and Exchange Commission (SEC or the commission) also instituted public administrative proceedings to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Altus Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in their required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.

Similar Private Companies By Industry

Company Name Region
Myndful United States
Phyllom LLC United States
RadioPharmacy Investors, LLC United States
Harkness Pharmaceuticals, Inc. United States
BIO-CAT, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Altus Pharmaceuticals Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.